Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

89%

8 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

7(77.8%)

N/A

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 4(7)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04405765Phase 4Completed

Cryopreserved vs. Lyopreserved Stravix as an Adjunct to NPWT in the Treatment of Complex Wounds

Role: collaborator

NCT03742440Phase 4Completed

GrafixPL PRIME Evaluation Case Study

Role: collaborator

NCT03629236Not ApplicableCompleted

Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers

Role: lead

NCT02571738Phase 3Terminated

Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers

Role: lead

NCT02675855Phase 4Completed

GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers

Role: lead

NCT02936128Phase 4Terminated

TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers

Role: lead

NCT02936115Phase 4Terminated

TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers

Role: lead

NCT02260609Phase 4Completed

GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds

Role: lead

NCT01596920Phase 4Completed

Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

Role: lead

All 9 trials loaded